March 20th 2023
Gary J. Schiller, MD, discusses the treatment for blastic plasmacytoid dendritic cell neoplasm and what clinicians need to look out for when evaluating these rare occurrences.
Pemmaraju Discusses Data, Approvals, and Challenges for Hematologic Malignancies
March 2nd 2023During a live Twitter Spaces event hosted by Targeted Oncology, Naveen Pemmaraju, MD, explained key abstracts from ASH 2022 and how these data have influenced recent approvals in the hematology field.
Read More
Biology Informs Treatment Options for Steroid-Refractory Chronic GVHD
February 22nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Noah M. Merin, MD, PhD, discussed biologic phases of chronic graft-vs-host disease and which therapies are available for patients who do not respond to steroids.
Read More
Acceptable Safety Seen With Orca-Q in the Haplo SCT Setting for High-risk Hematologic Malignancies
February 17th 2023At 1 year, the GVHD-and–relapse-free survival achieved with Orca-Q was 75%, which was noted to compare favorably with prior data reported in context of myeloablative conditioning , haploidentical stem cell transplant, and posttransplant cyclophosphamide.
Read More
Cytopenias Did Not Affect Ruxolitinib Efficacy in REACH2 Post Hoc Analysis
February 17th 2023Ruxolitinib elicited higher responses at day 28 compared with best available therapy in most cytopenia-based subgroups and had durable responses at day 56, according to a post hoc analysis of the REACH2 trial.
Read More
Ruxolitinib for GVHD in Patients < 2 Years Old Shows Variable Pharmacokinetics
February 17th 2023According to findings presented at the 2023 Transplantation & Cellular Therapy Meetings, experts did not identify clear correlation between the pharmacokinetics and pharmacodynamics of ruxolitinib in patients with graft-vs-host-disease.
Read More
Early Trial of Orca-T Produces 100% OS Rate in Hematologic Malignancies and 7/8 Mismatched Donors
February 17th 2023In 8 patients with various hematologic malignancies who received an allogeneic hematopoietic stem cell transplant with 7/8 non-permissive HLA mismatched donors, Orca-T led to a 100% survival rate.
Read More
Early Treatment With Ruxolitinib Induces High Response Rates in SR-aGVHD
February 17th 2023The phase 3 REACH2 trial showed that early treatment with ruxolitinib 10 mg led to higher response rates vs that seen with the best available therapy in patients with grade II-IV steroid-refractory acute graft-vs-host disease.
Read More
Real-World Data Shows Survival Improvement for aGVHD After Ruxolitinib Introduction
February 17th 2023Looking at a retrospective analysis of data from a single-center, the use of ruxolitinib decreased non-relapse mortality and improved overall survival for patients with steroid-refractory acute graft-vs-host-disease.
Read More
Review of Myelodysplastic Syndromes Aids Experts in Diagnosing and Treating Patients
December 27th 2022In an interview with Targeted Oncology, Justin Taylor, MD, discussed the recent changes that have been seen with this new classification of MDS and how this review article can help make people more aware of the treatment options available.
Read More
Treating Elderly Patients With ALL Remains a Challenge for Oncologists
December 16th 2022In an interview with Targeted Oncology, Marlise Luskin, MD, MSCE, discussed the challenges of treating adult and elderly patients with acute lymphoblastic leukemia and where new research in the space is headed.
Read More